INTRODUCTION: RNA-dependent protein kinase (PKR) is an independent prognostic variable in patients with non-small-cell lung cancer (NSCLC). In the current study, we investigated the correlation between PKR and 25 other biomarkers for NSCLC, identified the markers that could further improve the prognostic significance of PKR and elucidated the mechanisms of interaction between these markers and PKR. METHODS: Tissue microarray samples obtained from 218 patients with lung cancer were stained with an anti-PKR antibody and antibodies against 25 biomarkers. Immunohistochemical expression was scored and used for Kaplan-Meier survival analysis. The interaction between PKR and EphA2 in NSCLC cell lines was examined. RESULTS: We found that PKR was associated with EphA2 and that the prognostic information regarding NSCLC provided by the combination of PKR and EphA2 (P/E) was significantly more accurate than that provided by either marker alone. The 5-year overall survival rate in patients with PKR/EphA2 (20%) was significantly lower than that of patients with PKR/EphA2 (74%), patients with PKR/EphA2 (55%), and patients with PKR/EphA2 (55%) (p < 0.0001). We also found that the PKR:EphA2 (P/E) ratio was significantly associated with prognosis (p < 0.0001). Univariate and multivariate Cox analyses revealed that this P/E combination or ratio was an independent predictor of overall survival. In addition, induction of PKR expression reduced EphA2 protein expression levels in NSCLC cell lines. CONCLUSIONS: PKR/EphA2 is a significant predictor of prognosis for NSCLC. PKR/EphA2 may be a promising approach to improving screening efficiency and predicting prognosis in patients with NSCLC.
INTRODUCTION: RNA-dependent protein kinase (PKR) is an independent prognostic variable in patients with non-small-cell lung cancer (NSCLC). In the current study, we investigated the correlation between PKR and 25 other biomarkers for NSCLC, identified the markers that could further improve the prognostic significance of PKR and elucidated the mechanisms of interaction between these markers and PKR. METHODS: Tissue microarray samples obtained from 218 patients with lung cancer were stained with an anti-PKR antibody and antibodies against 25 biomarkers. Immunohistochemical expression was scored and used for Kaplan-Meier survival analysis. The interaction between PKR and EphA2 in NSCLC cell lines was examined. RESULTS: We found that PKR was associated with EphA2 and that the prognostic information regarding NSCLC provided by the combination of PKR and EphA2 (P/E) was significantly more accurate than that provided by either marker alone. The 5-year overall survival rate in patients with PKR/EphA2 (20%) was significantly lower than that of patients with PKR/EphA2 (74%), patients with PKR/EphA2 (55%), and patients with PKR/EphA2 (55%) (p < 0.0001). We also found that the PKR:EphA2 (P/E) ratio was significantly associated with prognosis (p < 0.0001). Univariate and multivariate Cox analyses revealed that this P/E combination or ratio was an independent predictor of overall survival. In addition, induction of PKRexpression reduced EphA2 protein expression levels in NSCLC cell lines. CONCLUSIONS:PKR/EphA2 is a significant predictor of prognosis for NSCLC. PKR/EphA2 may be a promising approach to improving screening efficiency and predicting prognosis in patients with NSCLC.
Authors: Urs von Holzen; Dora Bocangel; Abujiang Pataer; Stephan A Vorburger; Yanna Liu; Xialolin Lu; Kelly K Hunt; Stephen G Swisher Journal: Surgery Date: 2005-08 Impact factor: 3.982
Authors: Madhu Macrae; Richard M Neve; Pablo Rodriguez-Viciana; Christopher Haqq; Jennifer Yeh; Chira Chen; Joe W Gray; Frank McCormick Journal: Cancer Cell Date: 2005-08 Impact factor: 31.743
Authors: Jennifer M Brannan; Banibrata Sen; Babita Saigal; Ludmila Prudkin; Carmen Behrens; Luisa Solis; Wenli Dong; B Nebiyou Bekele; Ignacio Wistuba; Faye M Johnson Journal: Cancer Prev Res (Phila) Date: 2009-11-24
Authors: Jennifer M Brannan; Wenli Dong; Ludmila Prudkin; Carmen Behrens; Reuben Lotan; B Nebiyou Bekele; Ignacio Wistuba; Faye M Johnson Journal: Clin Cancer Res Date: 2009-06-16 Impact factor: 12.531
Authors: Jamel Mankouri; Mark L Dallas; Mair E Hughes; Stephen D C Griffin; Andrew Macdonald; Chris Peers; Mark Harris Journal: Proc Natl Acad Sci U S A Date: 2009-08-26 Impact factor: 11.205
Authors: Edwin R Parra; Carmen Behrens; Jaime Rodriguez-Canales; Heather Lin; Barbara Mino; Jorge Blando; Jianjun Zhang; Don L Gibbons; John V Heymach; Boris Sepesi; Stephen G Swisher; Annikka Weissferdt; Neda Kalhor; Julie Izzo; Humam Kadara; Cesar Moran; Jack J Lee; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2016-06-01 Impact factor: 12.531
Authors: Apar Pataer; Ruping Shao; Arlene M Correa; Carmen Behrens; Jack A Roth; Ara A Vaporciyan; Ignacio I Wistuba; Stephen G Swisher Journal: Cancer Med Date: 2018-04-19 Impact factor: 4.452
Authors: Chad Tang; Brian Hobbs; Ahmed Amer; Xiao Li; Carmen Behrens; Jaime Rodriguez Canales; Edwin Parra Cuentas; Pamela Villalobos; David Fried; Joe Y Chang; David S Hong; James W Welsh; Boris Sepesi; Laurence Court; Ignacio I Wistuba; Eugene J Koay Journal: Sci Rep Date: 2018-01-31 Impact factor: 4.379
Authors: George Sourvinos; Katerina M Antoniou; Ismini Lasithiotaki; Eliza Tsitoura; Anastasios Koutsopoulos; Eleni Lagoudaki; Chara Koutoulaki; George Pitsidianakis; Demetrios A Spandidos; Nikolaos M Siafakas Journal: Oncotarget Date: 2016-08-11